HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwasaki, A. Articles by Shirakusa, T. Search for Related Content PubMed PubMed Citation Articles by Iwasaki, A. Articles by Shirakusa, T. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2004;25:443-448
© 2004 Elsevier Science NL

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC

Second Department of Surgery, Fukuoka University, School of Medicine, 45-1-7 Chome Jonan-Ku, Nanakuma, Fukuoka 814-0180, Japan

Received 5 August 2003; received in revised form 18 November 2003; accepted 19 November 2003.

^* Corresponding author. Tel.: +81-92-801-1011; fax: +81-92-861-8271
e-mail: akinori{at}fukuoka-u.ac.jp

Objectives: Non-small cell lung cancer (NSCLC) tissue produces numerous growth factors, which are multifunctional and considered predictive of patient survival. This study sought to evaluate the relationship between concentrations of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) in NSCLC tissue and clinicopathological factors, and determine whether these factors correlate with long-term survival. Methods: We retrospectively investigated 71 patients with histologically confirmed adenocarcinoma or squamous cell carcinoma of the lung, for whom the primary curative approach was surgery, and who received no chemotherapy or radiotherapy prior to surgery. bFGF, VEGF, HGF were measured in extracts prepared from these 71 frozen tissue samples by ELISA. Five- and 10-year survival was obtained to determine the most important predictors of long-term survival. Results: Among clinicopathological parameters, the mean concentration of bFGF was significantly higher in tissue extracts from cases involving metastatic nodal involvement (87.5±69.3 ng/100 mg protein) than in those without nodal involvement (57.6±42.5 ng; P<0.05). Levels of VEGF in adenocarcinoma (26.8±34.0 ng) were higher than for squamous cell carcinoma (12.2±13.8 ng; P<0.05). HGF levels also demonstrated histological differences (14.7±7.7 vs. 10.6±9.7 ng, P<0.05). bFGF protein levels were basically the same, but showed no statistically significant differences with respect to histological type (72.5±55.2 vs. 63.6±51.5 ng). Patients with high levels of bFGF or VEGF showed significantly worse survival rates than patients with low levels (P=0.0059; P=0.0134). In particular, high concentrations of both bFGF and VEGF correlated with markedly poor prognosis (P<0.0001). Multivariate analysis indicated that lymph node involvement and levels of bFGF and VEGF were independent prognostic factors in cases of NSCLC (adenocarcinoma or squamous cell carcinoma) involving patients who had undergone curative resection. Conclusions: Adenocarcinoma associated with lung cancer is regarded to have biological characteristics that distinguish it from squamous cell carcinoma. Node invasion may be associated with bFGF. bFGF and VEGF augment each other and are associated with leading to poor prognosis. The results of this study suggests that effective therapy to block angiogenesis may need to address at least both of these factors in cases of NSCLC.

Key Words: Lung cancer • Angiogenetic factor • Histological type • Basic fibroblast growth factor • Vascular endothelial growth factor

This article has been cited by other articles:

				C. Behrens, H. Y. Lin, J. J. Lee, M. G. Raso, W. K. Hong, I. I. Wistuba, and R. Lotan Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6014 - 6022. [Abstract] [Full Text] [PDF]

				E. Zygalaki, E. G. Tsaroucha, L. Kaklamanis, and E. S. Lianidou Quantitative Real-Time Reverse Transcription PCR Study of the Expression of Vascular Endothelial Growth Factor (VEGF) Splice Variants and VEGF Receptors (VEGFR-1 and VEGFR-2) in Non Small Cell Lung Cancer Clin. Chem., August 1, 2007; 53(8): 1433 - 1439. [Abstract] [Full Text] [PDF]

				M. R. McClelland, S. L. Carskadon, L. Zhao, E. S. White, D. G. Beer, M. B. Orringer, A. Pickens, A. C. Chang, and D. A. Arenberg Diversity of the Angiogenic Phenotype in Non-Small Cell Lung Cancer Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 343 - 350. [Abstract] [Full Text] [PDF]

				L.-Z. Liu, J. Fang, Q. Zhou, X. Hu, X. Shi, and B.-H. Jiang Apigenin Inhibits Expression of Vascular Endothelial Growth Factor and Angiogenesis in Human Lung Cancer Cells: Implication of Chemoprevention of Lung Cancer Mol. Pharmacol., September 1, 2005; 68(3): 635 - 643. [Abstract] [Full Text] [PDF]

				R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]